Advanced Enzymes Q1 PAT Declines 5% YoY to ₹386 Mn

Date: August 08, 2026

| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 | YoY Change | QoQ Change | FY26 | FY25 | FY Change |

| Revenue (₹ Mn) | 1,898 | 2,034 | 1,859 | +2% | -7% | 7,458 | 6,369 | +17% |

| EBITDA (₹ Mn) | 510 | 632 | 564 | -10% | -19% | 2,291 | 1,944 | +18% |

| EBITDA Margin (%) | 27% | 31% | 30% | - | - | 31% | 31% | - |

| PAT (₹ Mn) | 386 | 453 | 404 | -5% | -15% | 1,736 | 1,340 | +30% |

| PAT Margin (%) | 20% | 22% | 22% | - | - | 23% | 21% | - |

| EPS (₹) | 3.31 | 3.84 | 3.57 | -7% | -14% | 15.08 | 11.72 | +29% |

Revenue from operations increased to ₹1,898 million in Q1 FY27 from ₹1,859 million in Q1 FY26, growth of 2%
Consolidated EBITDA decreased by 10% to ₹510 million from ₹564 million
Profit before tax decreased by 3% to ₹535 million from ₹549 million
Profit after tax decreased by 5% to ₹386 million from ₹404 million
EBITDA margin stands at 27%, PBT margin at 28%, PAT margin at 20%
Financial costs stood at ₹6 million compared to ₹8 million in Q1 FY26
Depreciation and Amortization charge stood at ₹99 million compared to ₹96 million

Revenue from operations decreased by 7% to ₹1,898 million from ₹2,034 million in Q4 FY26
Consolidated EBITDA decreased by 19% to ₹510 million from ₹632 million
Profit before tax decreased by 10% to ₹535 million from ₹598 million
Profit after tax decreased by 15% to ₹386 million from ₹453 million
Financial costs remained unchanged at ₹6 million
Depreciation and Amortization charge decreased to ₹99 million from ₹102 million

| Human Nutrition | 1,139 | 1,221 | -7% |

| Animal Nutrition | 252 | 260 | -3% |

| Bio-Processing | 306 | 236 | +30% |

| Specialized Manufacturing | 200 | 142 | +41% |

| Human Nutrition | 1,139 | 1,281 | -11% |

| Animal Nutrition | 252 | 250 | +1% |

| Bio-Processing | 306 | 324 | -5% |

| Specialized Manufacturing | 200 | 180 | +11% |

Human Nutrition: Decline of 7% YoY primarily attributable to lower sales in Pharma/API business
Animal Nutrition: 3% YoY decline in revenue
Bio-Processing: Strong performance with 30% YoY growth
Food business grew 51% YoY to ₹263 million
Non-Food business declined 30% YoY to ₹43 million
QoQ: Food business declined 5%, Non-Food business declined 8%
Specialized Manufacturing: Contributed 11% to total revenue, grew 41% YoY

Domestic sales: ₹937 million in Q1 FY27 (49% of revenue) vs ₹979 million in Q1 FY26 (53% of revenue), decline of 4% YoY
International sales: ₹961 million in Q1 FY27 (51% of revenue) vs ₹881 million in Q1 FY26 (47% of revenue), growth of 9% YoY
Regional performance YoY:
Americas: -3%
Europe: +44%
Asia (ex-India): +37%
Rest of the world: -15%
QoQ: International sales declined 1% from ₹973 million in Q4 FY26

Company launched its own nutraceutical brand "Wellfa" targeting Indian consumers
Product range includes immune support, skincare, gut health, metabolism enhancement, detox solutions, weight management, stress relief, and respiratory health
Selling through online platforms to diversify digital sales channels
Expected to become a key growth driver

Conducting trials and research to develop innovative nutritional products
Working to register and launch additional products in domestic and international markets
Expanding sales and marketing teams across USA, MENA, and Asian regions
Appointing new distributors in international markets

Introducing additional probiotic products in Human Nutrition segment focusing on immunity enhancement, active health foods, gut health, and nutraceutical applications
Launching new products in Animal Nutrition segment aimed at boosting immunity, improving digestion, and enhancing nutritional value

Developing biocatalysis for API manufacturers to reduce energy consumption, processing time, and chemical usage
Products at various development stages, with some in advanced plant-level trials with API manufacturers

Submitted 15 dossiers to European Food Safety Authority (EFSA), received positive opinions for 9
Expanding presence across Europe, Americas, and other global markets in baking industry

Company maintains zero-debt status, all past acquisitions financed through internal accruals
Completed four acquisitions over past nine years
Exploring strategic acquisition opportunities to enhance frontend marketing capabilities, expand geographical footprint, strengthen product portfolio, and bolster B2C business